Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Abbott Laboratories, common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Short-term borrowings 0.00 0.00 0.00 0.29 0.30
Trade accounts payable 5.87 6.19 5.86 5.44 4.79
Salaries, wages and commissions 2.18 2.09 2.16 1.95 1.82
Accrued rebates payable to government agencies 0.89 0.86 0.48 0.44 0.31
Accrued other rebates 1.49 1.46 1.44 1.11 0.96
All other 5.03 5.53 4.97 5.57 4.67
Other accrued liabilities 7.41% 7.85% 6.89% 7.12% 5.94%
Dividends payable 1.30 1.19 1.11 1.10 0.94
Income taxes payable 0.67 0.46 0.41 0.50 0.33
Current portion of long-term debt 1.48 3.02 1.00 0.01 1.88
Current liabilities 18.90% 20.81% 17.43% 16.41% 16.00%
Long-term debt, excluding current portion 18.57 19.51 23.00 25.54 24.54
Defined benefit pension plans and post-employment medical and dental plans for significant plans 2.68 2.40 3.64 4.30 4.15
Deferred income taxes 0.78 1.33 1.85 1.94 2.28
Operating lease liability, non-current 1.30 1.27 1.27 1.24 1.11
All other 4.73 5.11 4.90 5.08 5.81
Post-employment obligations and other long-term liabilities 9.49% 10.11% 11.66% 12.56% 13.35%
Long-term liabilities 28.06% 29.61% 34.67% 38.10% 37.89%
Total liabilities 46.97% 50.42% 52.09% 54.51% 53.89%
Preferred shares, one dollar par value, none issued 0.00 0.00 0.00 0.00 0.00
Common shares, without par value 33.97 33.19 32.54 33.28 35.14
Common shares held in treasury, at cost -21.83 -20.46 -15.72 -13.84 -14.95
Earnings employed in the business 51.29 47.36 41.93 38.08 38.07
Accumulated other comprehensive loss -10.71 -10.82 -11.14 -12.33 -12.47
Total Abbott shareholders’ investment 52.73% 49.28% 47.61% 45.19% 45.79%
Noncontrolling interests in subsidiaries 0.31 0.29 0.30 0.30 0.31
Total shareholders’ investment 53.03% 49.58% 47.91% 45.49% 46.11%
Total liabilities and shareholders’ investment 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Abbott Laboratories current liabilities as a percentage of total liabilities and shareholders’ investment increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Abbott Laboratories long-term liabilities as a percentage of total liabilities and shareholders’ investment decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Abbott Laboratories total liabilities as a percentage of total liabilities and shareholders’ investment decreased from 2021 to 2022 and from 2022 to 2023.
Total Abbott shareholders’ investment Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Abbott Laboratories total Abbott shareholders’ investment as a percentage of total liabilities and shareholders’ investment increased from 2021 to 2022 and from 2022 to 2023.